Instrument Inactif

Autres langues Cascadian Therapeutics Inc (USA)

Actions

US14740B6065

Recherche biotechnologique et médicale

Autres langues

04/01/18	Cascadian Therapeutics Announces 2018 Outlook and Recent Progress
02/01/18	Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
13/12/17	Cascadian Therapeutics Added to the Nasdaq Biotechnology Index
07/12/17	Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
08/11/17	Cascadian Therapeutics Reports Third Quarter 2017 Financial Results
01/11/17	Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017
24/10/17	Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November
27/09/17	Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer
20/09/17	Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
11/09/17	Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
28/08/17	Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress
08/08/17	Cascadian Therapeutics Reports Second Quarter 2017 Financial Results
01/08/17	Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017
11/07/17	Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe
08/06/17	Oncothyreon USA : Cascadian Therapeutics' Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
08/06/17	Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
31/05/17	Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference
09/05/17	Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET
01/05/17	Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017
05/04/17	Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017
13/03/17	Cascadian Therapeutics Announces Changes to Board of Directors
09/03/17	Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
27/02/17	Cascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
24/01/17	Cascadian Therapeutics Prices $82.5 Million Concurrent Offerings of Common Stock and Preferred Stock
23/01/17	Cascadian Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock